DINOMITE trial: papaverine for locally advanced rectal cancer
A US research institute has opened a phase 1 trial seeking to one day transform…
Author ONA Editor
ONA Editor
The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.
FDA approves cabozantinib for adults and paediatric patients 12 years of age and older with pNET and epNET
On March 26, 2025, the Food and Drug Administration approved cabozantinib (Cabometyx, Exelixis, Inc.) for…
Combining lenvatinib and pembrolizumab with transarterial chemoembolisation improves efficacy in treating hepatocellular carcinoma
An international collaborative research group led by Prof. Masatoshi Kudo, MD, Kindai University Faculty of…
Citrus remedy squeezes out dry mouth for cancer patients
A natural citrus oil from oranges, lemons, and limes is proving highly effective in relieving…
Blood cancer patients taking Bruton Tyrosine Kinase inhibitors should continue treatment at the time of COVID-19 vaccination
Blood cancer patients who receive a type of anti-cancer therapy should continue to take the…
Preventable paediatric cancer mortality surges in areas of armed conflict, exceeding rates in non-conflict regions
More than half of all paediatric cancer deaths worldwide occur in regions of armed conflict,…
Inhibition of PCSK9: a promising enhancer for anti-PD-1/PD-L1 immunotherapy
Immune checkpoint therapy, particularly anti-PD-1/PD-L1 immunotherapy, has achieved significant results in the treatment of various…
Study demystifies tumour formation’s two-step process — a foundational understanding needed to prevent cancer
Researchers at City of Hope®, one of the largest and most advanced cancer research and…
FDA approves dual-action drug for patients with previously treated advanced neuroendocrine tumours
Cabozantinib, an oral tyrosine kinase inhibitor, has been approved by the U.S. Food and Drug…
Digital PCR can reliably determine if chronic myeloid leukeamia patients in remission can successfully discontinue drug treatment
Researchers have found that the clinical application of BCR::ABL1 digital PCR can reliably quantify stable deep molecular…